Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.
Chiloiro S, Giampietro A, Mirra F, Donfrancesco F, Tartaglione T, Mattogno PP, Angelini F, Liverana L, Gessi M, Carmelo A, Rindi G, Giustina A, Fleseriu M, Pontecorvi A, De Marinis L, Bianchi A.
Chiloiro S, et al. Among authors: mirra f.
Eur J Endocrinol. 2021 Feb;184(2):217-229. doi: 10.1530/EJE-20-0767.
Eur J Endocrinol. 2021.
PMID: 33136550